All ongoing oncology clinical trials involving the removal of soluble TNFR
| Cytokine | Clinical trial ID | Phase | Number of patients | Cancer type | Treatment | Status | Estimated study completion date |
|---|---|---|---|---|---|---|---|
| TNFα | NCT04004910 | I/II | 170 | Advanced breast cancer | Three-way comparison between plasma soluble TNFR pulldown with or without chemotherapy, and chemotherapy alone | Recruiting | July 2023 |
| TNFα | NCT04142931 | I | 30 | Stage IV non-small cell lung cancer, stage IV melanoma, triple-negative breast cancer, or stage IV renal cell carcinoma | Reduction of soluble TNFR, with or without nivolumab | Recruiting | December 2022 |
| TNFα | NCT04690686 | II | 24 | Non-small cell lung cancer | Reduction of soluble TNFR alone, or with atezolizumab or paclitaxel | Recruiting | December 2022 |